Genentech presented new data on Esbriet (pirfenidone), a drug approved to treat idiopathic pulmonary fibrosis, at the 2015 American Thoracic Society Conference.

All three of Esbriet’s clinical trials involving 1,247 IPF patients showed impressive safety, tolerance, and efficacy as measured by significantly reduced loss of lung function by nearly 50% of participants, and decline in the 6-minute walk distance (6MWD) test by 27.5%.

When data from several studies were gathered and cross-examined, the drug was noted to reduce all-cause mortality by 48% compared to those who were on a placebo.

Get the full story at